Latest / CME Outfitters Medical Education / Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Inhibitors
Transcript
- 0:00SPEAKER_04: Hello.
- 0:01SPEAKER_04: On behalf of CME Outfitters, I'd like to welcome you to today's educational activity titled Reimagining Management of Generalized Myasthenia gravis, a focus on FCRN antagonists.
- 0:12SPEAKER_04: Today's program is supported by an independent educational grant from Argenics U.S.
- 0:17SPEAKER_04: Incorporated.
- 0:18SPEAKER_04: This activity may include discussions of products or devices that are not currently labeled for use by the FDA.
- 0:25SPEAKER_04: All conflicts of interest have been mitigated.
- 0:28SPEAKER_04: I'm Kristen Edmondson.
- 0:30SPEAKER_04: I'm the Director of Neuromuscular Medicine at the Swedish Neuroscience Institute in Seattle, Washington.
- 0:35SPEAKER_04: I'm joined today by a superb panel who I'll ask to introduce themselves, starting with Dr.
- 0:40SPEAKER_04: Neelem Goyal.
- 0:43SPEAKER_01: Hello, good evening.
- 0:44SPEAKER_01: Wonderful to be here.
- 0:45SPEAKER_01: I'm Neelem Goyal.
- 0:46SPEAKER_01: I'm a clinical professor of neurology and neurological sciences at Stanford University in the Division of Neuromuscular Medicine.
- 0:55SPEAKER_02: And I am Nicole Van Elles, nurse practitioner practicing at the Department of Neurology at Michigan State University in the Department of Neuromuscular Medicine and also Assistant Professor at the College of Nursing at Michigan State University.
- 1:11SPEAKER_04: Thanks so much for joining us today.
- 1:14SPEAKER_04: I'm really looking forward to a robust discussion of FCRN inhibitors in myasthenia gravis.
- 1:21SPEAKER_04: So we have several learning objectives today.
- 1:23SPEAKER_04: The first is to evaluate the mechanism of action, the safety and efficacy of FCRN antagonists in the treatment of generalized myasthenia gravis.
- 1:32SPEAKER_04: Second, we'll discuss how to identify patients with generalized myasthenia gravis who may be appropriate candidates for treatment with FCRN antagonists.
- 1:42SPEAKER_04: And finally, we'll discuss developing optimized and individualized treatment plans for patients with GMG who are on FCRN antagonists.
- 1:52SPEAKER_04: Now I'll hand things over to Neelam to talk about how FCRN antagonists work in myasthenia gravis.
- 1:58SPEAKER_04: Thank you so much, Neilam.
- 2:00SPEAKER_01: Thank you.
- 2:01SPEAKER_01: So let's start off with a question for the audience.
- 2:04SPEAKER_01: It'll give us a better sense of how familiar you all are with FCR antagonists.
- 2:09SPEAKER_01: So have you used an FCR antagonist to treat myasthenia gravis in your clinical practice?
- 2:34SPEAKER_01: All right, so it sounds like for about 17% of you, you um may be familiar, but have not found the right patient.
- 2:43SPEAKER_01: And for a vast majority, you don't have not seen or do not see patients with myisthenia or are not familiar with these agents.
- 2:51SPEAKER_01: So I think for those of you and and others, this will be a very um uh informational and formative session.
- 2:58SPEAKER_01: So, what are neonatal FC receptors and antagonists?
- 3:02SPEAKER_01: So the neonatal FC receptor, also referred to as FCRN, rescues IgG from cellular degradation.
- 3:10SPEAKER_01: And these antagonists block this action and result in degradation of IgG.
- 3:16SPEAKER_01: In generalized mycena gravis, this reduces the amount of circulating pathogenic antibody and thus leads to improvement in disease state.
- 3:26SPEAKER_01: Currently, there are three FDA-approved medications for the treatment of GMG that are FCRN antagonists, and these include F-Gartigamod, Rosanolixismab, and Nepocalamab.
- 3:38SPEAKER_01: And we have a few in development, including beta clemat.
- 3:43SPEAKER_01: Now we'll watch a brief animation about how FCRN antagonists work in mycena gravis.
- 3:50SPEAKER_00: Myasthenia gravis is a chronic antibody-mediated autoimmune disorder characterized by fatigable weakness of skeletal muscles.
- 3:58SPEAKER_00: It is driven by pathogenic IgG autoantibodies, which target components of the neuromuscular junction.
- 4:04SPEAKER_00: These antibodies impair neuromuscular transmission through receptor blockade, complement activation, or receptor internalization.
- 4:12SPEAKER_00: The persistence of these pathogenic autoantibodies is partly maintained by the neonatal FC receptor, or FCRN, a key regulator of IgG homeostasis.
- 4:23SPEAKER_00: FCRN binds IgG in acidified endosomes, protecting it from lysosomal degradation.
- 4:29SPEAKER_00: It then recycles IgG to the cell surface, where it re-enters circulation.
- 4:34SPEAKER_00: This process extends IgG half-life by approximately 21 days.
- 4:40SPEAKER_00: In autoimmune conditions like myasthenia gravis, this recycling pathway contributes to the sustained presence of pathogenic IgG autoantibodies to amplify and perpetuate disease activity.
- 4:51SPEAKER_00: FCRN antagonists are designed to disrupt this cycle.
- 4:55SPEAKER_00: These agents competitively bind FCRN, preventing its interaction with IgG, accelerating IgG catabolism.
- 5:03SPEAKER_00: This results in a rapid, dose-dependent reduction in circulating total IgG, including pathogenic autoantibodies.
- 5:11SPEAKER_00: Importantly, FCRN antagonists do not block the binding site for albumin on FCRN, so levels of serum albumin are not impacted by FCRN antagonists.
- 5:21SPEAKER_00: By exploiting a fundamental mechanism of IgG recycling, FCRN antagonists offer a novel, mechanism-based strategy to rapidly and selectively reduce the autoantibody burden and generalize myasthenia grapis.
- 5:36SPEAKER_01: Alright, that was a great animation.
- 5:38SPEAKER_01: So we'd like to just spend the next few minutes reviewing the clinical trial data from our three approved agents.
- 5:46SPEAKER_01: But before we do that, let's quickly talk about some outcome measures.
- 5:50SPEAKER_01: So first, and the the one that is our primary outcome measure in our clinical trials is the MGADL, which stands for Mycenae Gravis Activities of Daily Living.
- 6:01SPEAKER_01: Now, this is a patient-reported outcome measure.
- 6:04SPEAKER_01: We ask the patient to think about the last seven days and ask which of these symptoms they've had.
- 6:10SPEAKER_01: And we ask questions about three domains, ocular, bulbar, and limb.
- 6:16SPEAKER_01: The maximum score is 24, and the lowest would be zero, and a decrease of two points is considered clinically significant.
- 6:24SPEAKER_01: For MGADL and our other outcome measures, the higher the score, the more symptomatic the patient.
- 6:30SPEAKER_01: You may have heard of the term minimal symptom expression.
- 6:35SPEAKER_01: This implies an MGADL or zero or one.
- 6:38SPEAKER_01: And so this is a patient with no or very little disease activity.
- 6:45SPEAKER_01: QMG is different.
- 6:46SPEAKER_01: This stands for quantitative mycenia gravis score.
- 6:50SPEAKER_01: And as the name implies, this is an objective outcome measure.
- 6:54SPEAKER_01: So here we get the points based on what we see on exam.
- 6:58SPEAKER_01: We test strength in 13 areas.
- 7:00SPEAKER_01: This is primarily done in a research setting because it takes about 30 minutes to complete.
- 7:06SPEAKER_01: Again, the higher the score, the more severe the disease.
- 7:09SPEAKER_01: Zero is normal, and 39 is the maximum score.
- 7:13SPEAKER_01: A change of three or more points is considered clinically significant.
- 7:18SPEAKER_01: Now let's quickly review the clinical trial design and data for our three agents.
- 7:24SPEAKER_01: So our first in class was F.Gartigamod, and this was studied in a phase three adapt trial design.
- 7:31SPEAKER_01: This allowed patients that had mycena gravis with generalized disease that were both antibody positive or negative that had at least an MG ADL score of five or greater.
- 7:44SPEAKER_01: Upon entry, patients were randomized to either four-weekly infusions of F.Gartigamod or placebo and followed by a four-week off period.
- 7:54SPEAKER_01: The primary endpoint was the percentage of responders after this first treatment cycle that were ACHR antibody positive.
- 8:03SPEAKER_01: And a responder was a patient that had had a two-point or greater decline in their MGADL for at least four consecutive weeks.
- 8:13SPEAKER_01: The study went on for 26 weeks, and after that first cycle, patients were allowed another cycle if they had worsening of disease with their MGADL up to two points within their entry MGADL.
- 8:27SPEAKER_01: And then they went into an open label extension.
- 8:31SPEAKER_01: So here we see the results of the ACHR antibody positive patients after the first cycle.
- 8:37SPEAKER_01: And you can see the results of the patients in orange are those that were on FGAR Tigamod.
- 8:43SPEAKER_01: And you can see after treatment, both their MG ADL and QMG declined, which means that their symptoms got better and then slowly worsened again to baseline after the treatment was withdrawn.
- 8:57SPEAKER_01: Next, we move on to rosanolexisimab, which was studied in the phase 3 My Karengy trial.
- 9:03SPEAKER_01: This was different in that seronegative patients were not included, and they had an MGADL and a QMG criteria for entry.
- 9:12SPEAKER_01: Patients were randomized to placebo in two different doses of rosanolexismab, had weekly treatment for six weeks, and then had an observation period followed by open label extension.
- 9:25SPEAKER_01: The primary endpoint of this study was a change in MGADL score from baseline to day 43.
- 9:33SPEAKER_01: So here we have the results of MGADL and QMG.
- 9:37SPEAKER_01: In the maroon and the red, you can see the results for the low and the high dose of rosanolexisamab.
- 9:44SPEAKER_01: And similarly to F-Gartigamod, you see that after the treatment was started, both outcome measures were reduced, meaning the patients got better and then they returned to baseline when the treatment was stopped.
- 9:58SPEAKER_01: And lastly, nipochilomab was studied in the phase three vivacity and G3 trial.
- 10:05SPEAKER_01: Here, patients were randomized one-to-one to placebo or nipochalMab, which was given in a loading dose followed by a maintenance dose every two weeks.
- 10:16SPEAKER_01: This trial design is different in that patients were given continuous treatment.
- 10:21SPEAKER_01: The primary endpoint was mean change in MG ADL total score from baseline, average at weeks 22, 23, and 24.
- 10:33SPEAKER_01: And here again we see the results of the MG ADL and QMG with the results for NICOCLMAB in green.
- 10:40SPEAKER_01: And you can see after enrolling in the study, both MGADL and QMG had a decline, and this was maintained throughout the study.
- 10:51SPEAKER_01: Regarding side effects, all three agents are pretty well tolerated, and we see common side effects between all three.
- 10:59SPEAKER_01: Most commonly, we see side effects including headache and mild infections like URI and UTIs.
- 11:07SPEAKER_01: We can also see unique side effects like diarrhea, pyrexia, and peripheral edemia, peripheral edema in some of the agents.
- 11:17SPEAKER_01: Now that we know a little about the FCR antagonist for GMG, I'm going to hand things over to my colleague Nicole Vanales, who will talk about when these agents are appropriate for our patients.
- 11:31SPEAKER_02: Okay, thank you, Dr.
- 11:32SPEAKER_02: Goyle.
- 11:33SPEAKER_02: So first I want to start with a patient case.
- 11:38SPEAKER_02: So Amber is a 39-year-old woman who has been living with ACHR-positive generalized myasthenia graphs for two years and is seeing you for a regularly scheduled visit.
- 11:49SPEAKER_02: Amber is currently receiving IVIG, 2 grams per kilogram, every three weeks, and mycophenylate Mofadol, 500 milligrams twice a day.
- 11:59SPEAKER_02: She previously received prednisome but discontinued due to intolerance.
- 12:05SPEAKER_02: While she has seen symptom improvement with IVIG, she suffers frequent migraines and meningal symptoms.
- 12:12SPEAKER_02: Her MG ADL score is nine.
- 12:14SPEAKER_02: Amber would like to discuss potentially changing her medication due to her continued symptoms, which are negatively impacting her quality of life.
- 12:23SPEAKER_02: So given this information, what would you recommend for Amber?
- 12:46SPEAKER_02: Alright, so it looks like here, based on the question, it looks like uh we have uh we would the large percentage of you would discontinue IVIG and initiate an FCRN antagonist.
- 12:58SPEAKER_02: 12% of you of you would uh discontinue IVIG and initiate rituximab, um, and a small percent would either increase the mycophenylate or continue current treatment and re-evaluate in six months.
- 13:16SPEAKER_02: So here's a review of conventional therapies for generalized myocenea gravis.
- 13:22SPEAKER_02: There are both oral and intravenous options available.
- 13:25SPEAKER_02: And while the onset of action is relatively quick, with the use of IBIG, PLEX, and Rituximab, the oral alternatives may take several weeks, some months to achieve maximum efficacy.
- 13:37SPEAKER_02: None of these agents have been FDA approved for the treatment of GMG.
- 13:42SPEAKER_02: There are also additional health risks associated with using these agents, including those related to imine suppression and aphoresis.
- 13:50SPEAKER_02: This slide shows a recommended sequence of treatment posted from Belgium.
- 13:56SPEAKER_02: There's currently no single guideline for treatment, and we know that non-steroidal immune suppressant therapy is not ideal due to the prolonged onset of action and maximum efficacy.
- 14:07SPEAKER_02: This is an example of what may become a burdensome treatment course for the patient, including co-management with corticosteroids.
- 14:14SPEAKER_02: While this graph has a lot of information regarding the prevalence and mortality of MG over time, what I want to focus on is noticing the development of more effective therapies beginning around the mid-1950s.
- 14:26SPEAKER_02: There's been improvement of the lifespan of patients with MG as we have improved access to therapy.
- 14:33SPEAKER_02: However, there are still about 10 to 15% of patients who are treatment refractory.
- 14:38SPEAKER_02: Half of these patients are dissatisfied with their disease control on conventional therapy and feel that their symptom suppression is insufficient.
- 14:47SPEAKER_02: Here we have the MG ADL and QMG scores while on conventional therapies.
- 14:54SPEAKER_02: On the left is the MG ADL and on the right is your QMG scores.
- 14:59SPEAKER_02: On average, on the left for the MG ADL score, it was just over seven.
- 15:04SPEAKER_02: And remember, as Dr.
- 15:05SPEAKER_02: Goyle was explaining, minimum symptom expression is considered to be a score of two or less when we reviewed the data from the adapt trial.
- 15:13SPEAKER_02: The QMG score averages nearly 29 points.
- 15:17SPEAKER_02: Based on the screening tool, a score greater than 16 indicates severe disease.
- 15:22SPEAKER_02: So as you can see, there's really no meaningful improvement in MG symptoms using conventional therapy.
- 15:28SPEAKER_02: So this slide just shows that based on patient surveys, there is dissatisfaction of efficacy.
- 15:45SPEAKER_02: So this slide leads us to the advantages of FCRN antagonists.
- 15:50SPEAKER_02: Compared to conventional therapy, FCRN antagonists have a quick onset of action with maximum effectiveness in four to five weeks compared to several months, have more tolerable side effects, treatment leads to improved quality of life scores, there are customizable choices, and there is convenience of administration.
- 16:08SPEAKER_02: There are some disadvantages to consider before prescribing.
- 16:12SPEAKER_02: Some of these include the cost, having to trial conventional therapy and implications of social determinants of health, including employment and insurance implications.
- 16:22SPEAKER_02: For instance, many patients are unemployed and underinsured or uninsured due to the debilitating effects of poorly controlled MG symptoms.
- 16:32SPEAKER_02: There are some considerations prior to prescribing FCRN antagonists.
- 16:36SPEAKER_02: First is the patient selection.
- 16:38SPEAKER_02: FGARTICABOD is only approved for patients who are ACHR antibody positive.
- 16:44SPEAKER_02: Rosanolixumab and nipochlamad are only approved for patients who are either ACHR or MUSC antibody positive.
- 16:52SPEAKER_02: Nepocalaman is also approved for use in adolescents aged 12 to 17.
- 16:58SPEAKER_02: Depending on the FCRN antagonist, there are variable administration routes depending on the agent.
- 17:04SPEAKER_02: For instance, some have continuous dosing, some have cyclic dosing schedules, some are administered IV only, sub-Q, or newly approved for the pre-filled syringe.
- 17:17SPEAKER_02: Most are required to be administered by a healthcare professional.
- 17:21SPEAKER_02: IgG levels should be monitored regularly to assess risk for infection and immunization with live or live attenuated vaccines, is not recommended.
- 17:30SPEAKER_02: All FCRN antagonists have phase three data showing efficacy.
- 17:34SPEAKER_02: However, there are no head-to-head comparisons.
- 17:37SPEAKER_02: Each clinical trial had different trial designs and different definitions of treatment response.
- 17:42SPEAKER_02: However, each trial did show efficacy.
- 17:45SPEAKER_02: It will be up to you as the prescribing, as a prescriber, and your patient's individual needs to determine the best FCRN antagonist.
- 17:54SPEAKER_02: Other considerations include how long one agent should be tried before changing to another.
- 17:59SPEAKER_02: Would it be worth trying a different approved administration route within the same class?
- 18:04SPEAKER_02: And this is just a visual to remember that the patient is at the center of care and coordination is imperative.
- 18:14SPEAKER_02: So let's look again about how we would recommend a treatment change for Amber.
- 18:41SPEAKER_04: Thank you so much, both Kathleen and Neelam for reviewing that information.
- 18:47SPEAKER_04: We're going to shift into a faculty discussion at this point, but before we do that, I want to pose a couple of questions that have been queried by our audience.
- 18:57SPEAKER_04: So the first question is: can FCRN antagonists be combined with complement inhibitors?
- 19:03SPEAKER_04: Neelam, would you be willing to field that question?
- 19:06SPEAKER_01: Yeah, of course.
- 19:08SPEAKER_01: I think that's that's a really good question.
- 19:10SPEAKER_01: From a mechanism of action, an FCRN inhibitor and a complement inhibitor are doing two very different things.
- 19:19SPEAKER_01: One of the biggest issues is going to be, of course, costs, because these are both biological therapies and are both very expensive.
- 19:27SPEAKER_01: The other is that the majority of our complement inhibitors are monoclonal antibodies.
- 19:32SPEAKER_01: So the FCRN antagonists, as well as medications like IVIG and plasma exchange, are going to reduce their levels.
- 19:41SPEAKER_01: We do have one complement inhibitor, xyleucoplan, which is a small peptide that's given daily sub Q.
- 19:48SPEAKER_01: Because it's a small peptide, you can co-dose it with an FCRN.
- 19:53SPEAKER_01: So again, for a very refractory patient, you could consider co-dosing, but due to some of the limitations, this would really be in a very small percentage of our patients.
- 20:04SPEAKER_04: Great.
- 20:04SPEAKER_04: Thank you so much, Dr.
- 20:05SPEAKER_04: Goyle.
- 20:06SPEAKER_04: There are one or two other questions that I'd actually like to start our discussion, and I think we'll probably answer some of these questions over the course of the faculty discussion.
- 20:18SPEAKER_04: So I'd actually first like to start by posing a question to both of our fantastic panelists.
- 20:24SPEAKER_04: Whether an FCRN tag FCRN antagonist would be right for this patient in your opinion.
- 20:30SPEAKER_04: Is this a patient who we've been looking at that you would consider putting on an FCRN antagonist?
- 20:36SPEAKER_04: And are some of the other treatment options suggested also plausible?
- 20:39SPEAKER_04: And I guess I'd like to start with Kathleen and see what your thoughts are.
- 20:43SPEAKER_02: Yes, thank you, Dr.
- 20:45SPEAKER_02: Edmondson.
- 20:46SPEAKER_02: So yes, I think this patient would be a candidate for an FCRN antagonist.
- 20:51SPEAKER_02: She is still quite symptomatic with her generalized myasthenia gravis.
- 20:57SPEAKER_02: And it's something that she is, it is FDA approved for her to begin an FCR inhibitor given her antibody positive status.
- 21:07SPEAKER_02: I think what I like to encourage patients is the difference between the complement inhibitors and the FCRNs, where the monitoring is less.
- 21:20SPEAKER_02: Sometimes the ease of administration can be a deciding factor, especially if we use an example of the FGARTIGAMOD with the pre-filled syringe.
- 21:31SPEAKER_02: This is something after healthcare professional oversight, the patient can self-administer every week.
- 21:37SPEAKER_02: Great.
- 21:38SPEAKER_02: Thank you so much.
- 21:39SPEAKER_04: And Dr.
- 21:39SPEAKER_04: Goyle, I'm curious your thoughts as well.
- 21:42SPEAKER_01: Yeah, so I think there are many aspects about this patient that makes her a great candidate for FCRN.
- 21:48SPEAKER_01: She is ACHR antibody positive.
- 21:51SPEAKER_01: She has generalized disease.
- 21:53SPEAKER_01: And although we don't have her MGEDL, it sounds like, or maybe we did, I missed it, it sounds like it's above five.
- 21:59SPEAKER_01: So At least she meets the clinical trial criteria.
- 22:04SPEAKER_01: The main thing is that the IVIG doesn't seem to be working.
- 22:08SPEAKER_01: Steroids haven't worked in the past.
- 22:10SPEAKER_01: And thinking about her young age and all the side effects, it's probably not likely to work again.
- 22:16SPEAKER_01: So we're looking for a therapy that's going to work quickly, and FCRN would be a great choice.
- 22:22SPEAKER_01: I think my answer to the question that was posed before would be probably a combination of some of those things.
- 22:29SPEAKER_01: Mycophenylate, we have to be a little bit careful in women of childbearing age, but considering, you know, if she doesn't want to have any more children, or you've had that discussion, I would increase that dose to more therapeutic, which I consider to be about two to three grams a day, in addition to adding the FCRN antagonist.
- 22:49SPEAKER_01: And really the way I like to explain it is kind of upstream versus downstream.
- 22:55SPEAKER_01: With the mycophenylate, we are going to reduce the production of these pathogenic antibodies.
- 23:01SPEAKER_01: And with the FCRN antagonists, we can quickly remove those that are causing her symptoms and get her symptom-free.
- 23:09SPEAKER_04: Thank you so much for that.
- 23:11SPEAKER_04: And that actually sags really nicely into the next discussion topic I was hoping to address, which is how do you know when to move from conventional therapy like prednisone to some of these new advanced biologics like FCRN inhibitors?
- 23:23SPEAKER_04: And either Dr.
- 23:24SPEAKER_04: Van Elles or Dr.
- 23:24SPEAKER_04: Gloyle, I'm eager to hear your thoughts on sort of what triggers you might use to consider switching over from a conventional therapy to a more targeted therapy.
- 23:36SPEAKER_02: So when I when I consider switching therapy, I take the patient number one into consideration and I take a look at that MG ADL score.
- 23:43SPEAKER_02: So when I see patients, I have them complete an MG ADL for me on each visit.
- 23:48SPEAKER_02: And I can take a look at those trends and see if they are starting to trend up.
- 23:53SPEAKER_02: Even just a two-point change in that MG ADL score, either two-point higher or two-point lower, is significant.
- 24:00SPEAKER_02: This could be a patient that is that has gone from eating normally to now having to alter their diet because their oral muscles and swallowing muscles are weak.
- 24:10SPEAKER_02: So I take a look at that.
- 24:13SPEAKER_02: And then I also take a look at how they've been tolerating the medication that the conventional medication they are on so far, take a look at their age and consider if this is an elderly woman or a woman over the age of 65.
- 24:26SPEAKER_02: I don't want to continue corticosteroids any longer than I have to.
- 24:30SPEAKER_02: If I have a type 2 diabetic and who has comorbid type 2 diabetes with the generalized MG, I certainly need to be looking after that as well.
- 24:40SPEAKER_02: So they're let's very it can be very, very patient-specific, but the the main thing I'm looking for at is that MG ADL score.
- 24:46SPEAKER_02: And if I'm watching it creep up and I see my patients roughly every three to six months, depending on how stable they are, that is an indication of needing a change.
- 24:56SPEAKER_04: Great.
- 24:56SPEAKER_04: Thank you so much, uh Dr.
- 24:58SPEAKER_04: Van Ellis.
- 24:58SPEAKER_04: Dr.
- 24:58SPEAKER_04: Goyle, um, any additions to that in terms of when you consider moving from conventional therapy to the neurobiologics?
- 25:05SPEAKER_01: Yeah, so I agree with my colleague.
- 25:08SPEAKER_01: Really, you know, I think we can take a step back.
- 25:10SPEAKER_01: And the question can be when do you want to change a therapy for your patient?
- 25:14SPEAKER_01: What are the signs that the medications aren't working?
- 25:17SPEAKER_01: And really, it's what was mentioned, it's that the symptom burden is increasing.
- 25:22SPEAKER_01: And I would add the toxicity symptom is a burden is increasing.
- 25:26SPEAKER_01: So a patient may have an MGADL of zero and high dose steroids, but have tons of side effects that are impacting their day-to-day life.
- 25:35SPEAKER_01: And so it's really thinking about meeting the treatment goals for the both for the patient and for yourself, and then realizing when a change is necessary.
- 25:46SPEAKER_01: The benefit of about our biologics is that they do work very quickly.
- 25:50SPEAKER_01: And some of our conventional therapies, especially the non-steroidals, can take almost a year to work.
- 25:56SPEAKER_01: So also thinking about when do I expect this medication to work can also help you decide which um tool you want to go for in your toolkit.
- 26:06SPEAKER_04: Great.
- 26:07SPEAKER_04: Thank you so much.
- 26:08SPEAKER_04: And as sort of an add-on question to this that's been posed by an audience member, um, is how long do you try steroids before switching uh to an FRN antagonist?
- 26:17SPEAKER_01: The good thing about steroids is that they work very well and they actually work pretty quickly.
- 26:23SPEAKER_01: So we say that steroids typically work in about two to four weeks.
- 26:26SPEAKER_01: So I would say if you have a patient on a good dose, and I would say that it's probably anything above 20 milligrams, 20 to 40, let's say, and you see them back a month later and they've really had no benefit, then I would quickly move on to the next agent or be adding things.
- 26:43SPEAKER_01: If let's say they come back and they are doing well, but then they have a lot of side effects, so you start to taper and they quickly have a re-emergence of symptoms, then I'll be going for another medication.
- 26:54SPEAKER_01: So when starting patients on steroids, and especially high dose and that I would say anything above 20 milligrams, I would monitor patients very closely.
- 27:03SPEAKER_01: Um, there are many patients that do quite well on conventional therapy with steroids and are non-steroidals, but they require close monitoring to make sure that you're not missing remaining symptoms and the need to advance therapy.
- 27:18SPEAKER_01: Thank you so much.
- 27:20SPEAKER_04: Um, sort of uh to something that you had said about, you know, trying steroids and then potentially quickly switching to uh a newer biologic, um, is there a role for FCRN antagonists in earlier lines of therapy?
- 27:34SPEAKER_04: Are there instances that uh you, Dr.
- 27:36SPEAKER_04: Goyle or you, Dr.
- 27:37SPEAKER_04: Van Ells, would consider using FCRN inhibitors uh early before you've tried other more traditional agents in myasthenia gratis?
- 27:48SPEAKER_02: I think the data does support that if you do have a positive antibody, the data supports the use of an FCRN antagonist.
- 27:56SPEAKER_02: And I think that helps protect the patient from unwanted side effects, putting these patients at risk for different cancers using the non-steroidal immunosuppressant therapy, putting them at risk for osteoporosis, diabetes, uh, peptic ulcers, and things like that.
- 28:12SPEAKER_02: Um, so I think I think there is a place for that.
- 28:15SPEAKER_02: I think the data supports that, that this is definitely an option.
- 28:20SPEAKER_04: Absolutely.
- 28:21SPEAKER_04: I I agree with that.
- 28:22SPEAKER_04: And to sort of answer my own question and chime in as well, I actually don't necessarily see use of some of the traditional agents and the neurobiologics as being mutually exclusive.
- 28:33SPEAKER_04: That especially with the sort of rapid onset of action of FCRN inhibitors and some of the other targeted agents, I oftentimes if a patient has really severe symptoms that aren't um adequately mitigated by uh by steroids, I'll consider using these agents early while at the same time starting a steroids-bearing oral therapy with the idea that that may enable us to come off of the novel agent further down the road.
- 28:58SPEAKER_04: So we can sometimes consider these a bridge therapy as well to help bring disease under control uh quickly in some of our more severe patients.
- 29:07SPEAKER_01: Yeah, and I and I would say some patients just don't want to be on steroids.
- 29:11SPEAKER_01: You know, they are they've been on it for something else or in they or they've heard about it and they're just absolutely not willing.
- 29:18SPEAKER_01: And I think that's uh absolutely a situation if the disease burden is high enough where I would go for an FCRN antagonist early in the disease course.
- 29:27SPEAKER_04: Absolutely.
- 29:28SPEAKER_04: Now, interesting uh question from our audience.
- 29:31SPEAKER_04: Are there patients who you wouldn't consider using FCRNs in?
- 29:35SPEAKER_04: Like, are there some folks that you uh features you might look at in a patient and say this is not a good uh candidate for FCRN inhibition?
- 29:45SPEAKER_02: I'll say the only patient that I can think of that would not be a good candidate would be the patient who is unable to continue with the cyclic therapy.
- 29:54SPEAKER_02: So patients who have um difficulty with transportation, patients who are unable to uh give themselves their own injection using the pre-filled syringe.
- 30:04SPEAKER_02: I think that would really be what would inhibit me from prescribing to a patient, would be those those those needs.
- 30:13SPEAKER_02: Thank you.
- 30:14SPEAKER_02: Dr.
- 30:14SPEAKER_04: Mark, you're the one who you would not give an FCRN to.
- 30:19SPEAKER_01: Yeah, I think in our community we think about FCR antagonists like plasma exchange.
- 30:26SPEAKER_01: So if a patient was admitted for crisis and had plasma exchange and didn't respond, that might be a patient where I may pause and say, hmm, will FCRN inhibitor work or not?
- 30:38SPEAKER_01: But to be honest, I don't recall that situation.
- 30:41SPEAKER_01: And I think mostly it becomes an insurance issue.
- 30:45SPEAKER_01: Do they have antibody positive disease?
- 30:48SPEAKER_01: And then just as some patients can feel strongly about not wanting to be on steroids, there's some patients that feel strongly about not being on infusion therapy, and so they favor the oral medication.
- 31:00SPEAKER_01: So, you know, kind of bringing into that um shared decision making.
- 31:04SPEAKER_01: We did see a high incidence of headaches.
- 31:07SPEAKER_01: So patients that have low IgG or um issues with chronic infections, now that may not prompt me to not start because all of the other medications will also suppress the immune system other than IVIG, but I may take the patient off quickly if um infections was becoming or headaches was becoming an issue.
- 31:31SPEAKER_04: Thank you so much.
- 31:31SPEAKER_04: And sort of a follow-on logistical question to that.
- 31:34SPEAKER_04: In your practices, do you monitor IgG levels in patients who are on FCRN inhibitors?
- 31:41unknown: Dr.
- 31:41SPEAKER_04: Glyle?
- 31:43SPEAKER_01: Um I do not.
- 31:44SPEAKER_01: So for the um clinical trial, you did have to have a baseline IgG level above six, but in the label, there's no requirement for monitoring.
- 31:55SPEAKER_01: Um, if I have a patient that's having infections, I may check, but to be honest, I have not checked in any of my patients.
- 32:02SPEAKER_02: And neither do I.
- 32:04SPEAKER_04: You know, yeah, I don't, I don't either.
- 32:06SPEAKER_04: I think the only exception to that is if I'm using an off-label um dosing schedule, which we'll talk more about after our next uh series of slides and in our next faculty discussion.
- 32:16SPEAKER_04: If I'm if I'm uh using an off-label dosing regimen, I will sometimes check periodically to be sure that we're not um not getting into a dangerous range.
- 32:25SPEAKER_04: Um and then one of the final questions in um in this uh segment of discussion is you know, we have we have three FCRN inhibitors that are approved.
- 32:34SPEAKER_04: We have um F-gartigamod, which is sort of cyclic dosing with cycles of four weeks and has both IV and subcutaneous self-administered options, rosinoluxizimab, which is a cyclic dosing of six weeks on, four weeks off, um subcutaneous, and then nepocalamab, which is IV, but every two-week continuous dosing.
- 32:53SPEAKER_04: How do you choose which FCRN inhibitor to try?
- 32:56SPEAKER_04: What sort of factors do you consider when you know you've identified, okay, this patient may benefit for an FCRN antagonist?
- 33:03SPEAKER_04: Um, are there things that are driving you to choose between FGR Tigamod, rosenolxisomab, or nepocalamab?
- 33:11SPEAKER_02: I think based on the data that we have from those phase three trials, we do see that they they are all efficacious.
- 33:17SPEAKER_02: So I think it comes up against um insurance challenges as well as uh patient availability.
- 33:24SPEAKER_02: As FGAR Tigamod has had the new indication for or a new route for pre-filled syringe.
- 33:30SPEAKER_02: I have had patients requesting to come out of the IV infusion center, or they don't want to do home infusions anymore, or uh they want to do um home self-administration.
- 33:40SPEAKER_02: Um, so you know, a lot of it it's it's kind of patient specific, but also driven by insurance coverage.
- 33:48SPEAKER_04: Great.
- 33:48SPEAKER_02: Thank you.
- 33:49SPEAKER_04: Yeah.
- 33:50SPEAKER_04: Dr.
- 33:50SPEAKER_04: Boyle, any other thoughts on that, choosing between the different agents that are available?
- 33:55SPEAKER_01: Yeah, I agree.
- 33:56SPEAKER_01: I I think, you know, because we don't have head-to-head studies, hard to say that one is better than the other.
- 34:02SPEAKER_01: I would say all three are a little bit different with cyclical versus continuous, um, which antibody positivity we can use them for, musk or not able to use for musk, uh, pediatric population.
- 34:16SPEAKER_01: Um, and so I think some of those factors plus local insurance issues can really um factor into which medication we go for first.
- 34:27SPEAKER_04: Thank you.
- 34:28SPEAKER_04: And then just a couple of sort of quick functional questions from our audience.
- 34:32SPEAKER_04: Um, first is for FGAR Tigmod once a week with four cycles, with four weeks cycles, how can soon can it be repeated?
- 34:40SPEAKER_04: Uh, Dr.
- 34:40SPEAKER_04: Van Ells, if you could feel that one.
- 34:42SPEAKER_04: How quickly how soon can you repeat a cycle of F-Gartigmod?
- 34:45SPEAKER_02: Yeah, so we repeat a cycle in four weeks.
- 34:48unknown: Yeah.
- 34:49SPEAKER_04: And then um, sort of follow-on if you'd be willing to answer, Dr.
- 34:52SPEAKER_04: Van Ells, um, how many cycles of F-Gartigmod do you consider adequate to determine if someone is a non-responder?
- 34:58SPEAKER_02: So I typically like to give my patients about three cycles to see how they've done.
- 35:03SPEAKER_02: Um, anecdotally, I can I can speak to that.
- 35:06SPEAKER_02: That's about the about the time frame where we're gonna see um if they've had a symptom improvement or not.
- 35:13SPEAKER_02: And I think that, you know, the data from the adapt trial can help support that too.
- 35:17SPEAKER_02: We had the uh the the first cycle, and then we had, or the first adapt, then we had the adapt extension that did show, you know, that there was some improvement doing that second cycle of it.
- 35:28SPEAKER_02: I have them go one more cycle.
- 35:30SPEAKER_02: Um what I have seen that if if FGAR Tigamod, uh, if we've changed routes, it often takes one cycle to get them into a newer level of baseline and improvement.
- 35:42SPEAKER_02: Um, so that's what I've seen anecdotally.
- 35:44SPEAKER_04: Thank you so much.
- 35:46SPEAKER_04: So this has been a great discussion, and I want to be cognizant of the time.
- 35:50SPEAKER_04: Um, so I think we'll hand things back over um to Neelam to tell us a little bit about how to individual individualized dosing of FCR and antagonists for our patients.
- 35:59SPEAKER_01: Right, thank you.
- 36:00SPEAKER_01: Um, that was a great discussion.
- 36:02SPEAKER_01: So we'll come back and uh come back to Amber.
- 36:05SPEAKER_01: So, like many of you suggested, the uh Amber was her IVIG was stopped and she was started on an FCR and antagonist, FGAR Tigmod, sub Q once weekly on a schedule of four weeks on and four weeks off.
- 36:18SPEAKER_01: She responded well to treatment and sees an improvement in symptoms within one cycle.
- 36:24SPEAKER_01: She continues to experience benefit with each subsequent cycle FGAR Tigmod.
- 36:29SPEAKER_01: While Amber's symptoms are improving during her symptom cycles, she reports an early return of symptoms, usually about a week after the beginning of each treatment cycle.
- 36:41SPEAKER_01: So, how what would you recommend for Amber?
- 37:01SPEAKER_01: Right.
- 37:02SPEAKER_01: So it looks like the vast majority would alter her dosing schedule to give her four weeks on and three weeks off.
- 37:10SPEAKER_01: And our next um was increase mycophenylate to a thousand BID, and a small percentage wanted to continue and see how she did in the next few months.
- 37:22SPEAKER_01: All right.
- 37:23SPEAKER_01: So we've alluded to the differences between the FCR and antagonist, but let's review them now.
- 37:29SPEAKER_01: So all three agents do differ a bit on how we can deliver them, how long the infusions take, the dosing and the schedule.
- 37:39SPEAKER_01: And this can all be part of your decision making of when to use what agent.
- 37:44SPEAKER_01: So FGR Tigamod is available in an IV formulation, which is weight-based, infused over an hour and given four weeks on and four weeks off.
- 37:55SPEAKER_01: It is also available in a subcutaneous formulation with the do with a fixed dose.
- 38:02SPEAKER_01: And most recently, pre-filled syringes were also available.
- 38:06SPEAKER_01: So these pre-filled syringes can actually be self-administered by the patient, whereas the sub Q requires a healthcare professional for administration.
- 38:16SPEAKER_01: The administration is very quick within less than one minute, and it's also given four weeks on and four weeks off.
- 38:24SPEAKER_01: Rosanolexismab is given subcutaneous and it requires a specialized pump.
- 38:30SPEAKER_01: It requires healthcare professional for administration.
- 38:34SPEAKER_01: It's given in three doses based on the patient's weight.
- 38:38SPEAKER_01: The dosing is over 15 minutes and it's given over three uh six weeks, uh, six weekly um dosing, followed by four weeks off.
- 38:48SPEAKER_01: And nipokelamab, which is the newest uh FCRN approved just a few months ago.
- 38:54SPEAKER_01: This is intravenous.
- 38:56SPEAKER_01: This is given in a loading dose of 30 milligrams per kilogram, followed by continuous dosing every two weeks of the maintenance dose, which is 15 milligrams per kilogram, given over 30 minutes.
- 39:11SPEAKER_01: Now, these very unique aspects of these different agents allow us to individualize dosing for FCRN antagonists.
- 39:20SPEAKER_01: For those agents that are given in a cyclic dosing form, this offers an option for personalization.
- 39:28SPEAKER_01: So during treatment breaks between cycles, when the patient is not on the medication like Amber, some patients experience an early return of symptoms.
- 39:37SPEAKER_01: So cycles can be shortened or lengthened to address continued symptoms or emergent adverse events.
- 39:45SPEAKER_01: So, for example, if a patient doesn't have symptoms in cyclical dosing, by the time they're ready for their next cycle, you could consider lengthening the time between the cycles.
- 39:56SPEAKER_01: FGR tigamod, as we had discussed before, after the first eight weeks of the first cycle in the 26-week adapt trial, the next cycle of FGAR Tigamod was based on patient response, so how they were doing.
- 40:13SPEAKER_01: FGAR Tigamod was also studied in the adapt next study, which we'll talk about in a little bit, which compared two dosing regimens of fixed cycle versus continuous dosing of F-Gartigamod.
- 40:27SPEAKER_01: Rosanolyx of the MAB, which we had discussed before, was studied in the MyCARE and phase three study, where there were six weekly infusions followed by an observation period.
- 40:37SPEAKER_01: This had a placebo arm.
- 40:39SPEAKER_01: After this, the patients could enroll into two open label arms.
- 40:43SPEAKER_01: The MGO07 allowed for patients to be in the low dose or the high dose and get and get next cycle based on how their symptoms were doing.
- 40:53SPEAKER_01: And O04 studied Rosanolitzimab in a fixed continuous dosing cycle.
- 41:00SPEAKER_01: And so here we have the results of the Adapt Next study.
- 41:04SPEAKER_01: So the in the Adapt Next study, after patients were enrolled, all of them received four weekly cycles of FGARtigmod, and then they were randomized to either get four weeks on or four weeks off, or get an infusion every two weeks.
- 41:19SPEAKER_01: And you can see the results on the right, and these are the MG ADLs, and you can see that the MGADL was quite similar between the two groups.
- 41:28SPEAKER_01: And so there was no statistical significance in the MGADL between these two groups.
- 41:33SPEAKER_01: Also, the adverse events were similar if you gave it every other week or in a continuous format, with most common uh side effects being headache and mild infection.
- 41:46SPEAKER_01: Here are the results of MG007.
- 41:49SPEAKER_01: So just to remind ourselves, this was the uh open label extension where patients were on low dose or high dose Rosanellixis map, but the next cycle was based on how they were doing in terms of their symptoms.
- 42:04SPEAKER_01: So to orient you to the graph, on the x-axis we have the time interval between their next cycle and on the y-axis, we have percentage of patients.
- 42:16SPEAKER_01: And the different color graph uh bar bar represent the time between their first and second cycle, third, fourth, and so forth.
- 42:25SPEAKER_01: And so, really, the takeaways here are that the majority of patients were able to go about four to eight weeks between their cycles.
- 42:35SPEAKER_01: Um, and the other takeaway is that you do have some patients, a small percentage, about 10% or less, that required it even earlier at less than four weeks.
- 42:46SPEAKER_01: And then there were some patients, you know, up to 22% that were able to even go longer, 12, 24, even 24 weeks, 36 weeks before they required their next dose.
- 43:00SPEAKER_01: So, really allowing for that personalization of treatment for these patients.
- 43:05SPEAKER_01: And so now that we've reviewed this data, let's go back to that same question that we asked.
- 43:11SPEAKER_01: So, now having reviewed that data, would you do anything differently?
- 43:15SPEAKER_01: So, what would you recommend for Amber?
- 43:35SPEAKER_01: All right, so um I think we have the same number or percentage that want to go to four weeks on, four weeks off, but we have lost our folks that wanted to increase her mycophenylate and have moved a bit to switching to uh Rosie or continuing her current regimen and reevaluating in three to six months.
- 44:00SPEAKER_04: Right.
- 44:00SPEAKER_04: Thank you so much for that additional information, Neilam.
- 44:03SPEAKER_04: It's really helpful to see that data on the sort of way each medication is dosed and where there may be flexibility, maybe some flexibility within each of those.
- 44:15SPEAKER_04: Before we move on to a more robust discussion of sort of personalized dosing and FCRN inhibition, I want to be sure to answer a question from earlier that was posed a little bit earlier by one of our listeners.
- 44:28SPEAKER_04: When would you pick an FCRN inhibitor over IVAG or Plex, particularly now in light of this information we've presented about the sort of flexibility and adjustability of the FCRN inhibitors?
- 44:40SPEAKER_04: Dr.
- 44:40SPEAKER_04: Goyal, would you mind yielding that one?
- 44:43SPEAKER_01: Sure.
- 44:44SPEAKER_01: So plasma exchange, I think the practice can be quite variable based on where you practice.
- 44:51SPEAKER_01: So for us at Stanford, it's it's quite challenging to get plasma exchange.
- 44:57SPEAKER_01: So for me, plasma exchange is really reserved for patients that are very refractory and I'm not able to get them under control with other agents.
- 45:05SPEAKER_01: But I think the question regarding IVIG and FCRN inhibition is a really important one.
- 45:10SPEAKER_01: And I would say that for a new start, so this is a patient presenting with moderate MG, they've been on steroids and it's not working, or they don't want to be on steroids and I'm looking for a quick acting therapy.
- 45:23SPEAKER_01: I do go for FCRN inhibition over IVIG.
- 45:27SPEAKER_01: With IVIG, you know, it definitely works very well, but there are issues regarding just access.
- 45:34SPEAKER_01: A couple of years ago, we had an IVIG shortage.
- 45:37SPEAKER_01: And so I think, and the data as well, we have robust clinical trial data that this medication works.
- 45:44SPEAKER_01: In one case where I may go for IVIG, is that we know that about 10% of our patients will present in crisis.
- 45:52SPEAKER_01: So if they presented in crisis and in the hospital have responded very well to IVIG, I may choose to continue that versus switch them over to an FCR inhibitor.
- 46:04SPEAKER_04: Great.
- 46:04SPEAKER_04: Thank you so much.
- 46:05SPEAKER_04: Dr.
- 46:05SPEAKER_04: Van Ellis, anything to add there?
- 46:07SPEAKER_02: Uh yeah, just uh one other couple other things to add.
- 46:11SPEAKER_02: Um, in terms of tolerance of PLX and counterindications for use of IVIG, if we do have patients that um have had any kind of clotting episodes, DBTPE, um, patients that may have a history of heart failure, IVIG might not be the right choice for them.
- 46:29SPEAKER_02: Um, and then for plasma exchanges, the tolerance of it, patients are pretty wiped out.
- 46:33SPEAKER_02: Um, if you can liken it with dialysis, often patients often feel that sort of fatigue after that.
- 46:41SPEAKER_04: Absolutely, thank you both.
- 46:43SPEAKER_04: Um so launching back into our discussion of sort of personalizing and individualizing FCRN inhibition, um, I'm wondering in your current practice, and maybe Dr.
- 46:53SPEAKER_04: Van Elles, you can feel this, is there a way that you typically start FCRN inhibitors with each of these agents?
- 46:59SPEAKER_04: Um, do you start with a single cycle and then see how they do?
- 47:03SPEAKER_04: Do you plan on giving a certain number of cycles at a fixed, at a fixed cadence and then adjusting from there?
- 47:10SPEAKER_04: How do you do you start off with something that's sort of um uh typical for you, or do you personalize the dose or regimen from the beginning?
- 47:20SPEAKER_02: Yeah, thank you for that question.
- 47:21SPEAKER_02: So I will I will start with kind of a a standard, I will set them up for three cycles.
- 47:29SPEAKER_02: Um, but I do see them back after the first cycle to see how they've responded, to go over any um headache is definitely the the number one um common adverse reaction to this, to any of these agents.
- 47:42SPEAKER_02: So I will set for at least three cycles, but see them back after the first um and then personalize from there depending.
- 47:49SPEAKER_02: If they tolerated it well, they found they've had some improvement, and I can base that on that MG ADL, I'll let them continue.
- 47:56SPEAKER_02: And if they've remained stable, the woman will continue as such.
- 48:00SPEAKER_02: If they had complete fall-off of symptoms and or fall off and had uh return of symptoms, I may adjust even going on that second cycle, just depending on on how the patient did.
- 48:10SPEAKER_04: Yeah.
- 48:11SPEAKER_04: And for those uh to follow up on that um with you, for those first set of cycles, whether it's you know F-Gartigamod or Rosanolxisamab, do you do those at the maximum frequency, four weeks on, four weeks off for F-Gartigamod, six weeks on, four weeks off for rosinoluxisimab, or do you start with a different cadence?
- 48:30SPEAKER_02: I I do start with that original cadence of those original studies, the four weeks on and four weeks off for the F-Gartigamod, and then for the Rosie, the six weeks on and four weeks off, and I start there.
- 48:41SPEAKER_04: Okay, great.
- 48:42SPEAKER_04: Dr.
- 48:42SPEAKER_04: Goyal, is that your practice as well?
- 48:45SPEAKER_01: Yeah, I think when FGAR Tigamod first came out, we were struggling with, you know, do we just give them the four weeks and then try to see how they're doing to decide the next dose?
- 48:55SPEAKER_01: And I think there's just a lot of practical challenges to that.
- 48:58SPEAKER_01: So um I agree with my colleague.
- 49:00SPEAKER_01: I, you know, give them um, I order it for let's say six months or whatever insurance allows and more fixed cycles, but then really communicate regularly to see if things need to be changed.
- 49:13SPEAKER_04: Absolutely.
- 49:14SPEAKER_04: And then, Dr.
- 49:15SPEAKER_04: Goyle, in your clinical practice, do you see much wearing off?
- 49:18SPEAKER_04: Do you have issues with those sorts of like that that cyclical dosing for for Rosie and for F Gratigmod?
- 49:25SPEAKER_01: Yeah, I think uh Amber is a great case because you know it shows that she responded really well, but she did have that wearing off.
- 49:33SPEAKER_01: And so, yes, absolutely.
- 49:35SPEAKER_01: I I would say that I have more patients that have experience wearing off than those that I was able to go longer.
- 49:43SPEAKER_01: Um, but having those patients where you can go longer is great because they have to have you know less um treatment um exposure.
- 49:51SPEAKER_01: Um, but yeah, for those patients that are having a wearing off, uh, you know, trying to see if insurance can allow for earlier dosing, and then really seeing if there are other ways like their um non-steroidal or optimizing their other medications to really get their general disease better so that we can have um, you know, just better treatment responses from the FCRN as well.
- 50:15SPEAKER_04: Thank you.
- 50:15SPEAKER_04: And that actually leads nicely into a question posed by an audience member is have you run into issues getting alternative dosing schedules approved by insurance?
- 50:25SPEAKER_02: And I have not to date.
- 50:27SPEAKER_02: Really?
- 50:28SPEAKER_02: Once they're established on therapy, um, I have not.
- 50:31SPEAKER_02: And I I share Dr.
- 50:33SPEAKER_02: Goyle's practices.
- 50:34SPEAKER_02: Um, I have seen, I've had good experience of patients uh having wear-off symptoms and having to adjust.
- 50:42SPEAKER_02: Um, and so far, no problem.
- 50:44SPEAKER_02: I'm practicing in Michigan, and so I don't know if it's a state-to-state um type of difference, but yeah, I I have definitely had insurance issues.
- 50:54SPEAKER_01: I think the four weeks on, four weeks off going to every other week, the total dose is the same.
- 51:01SPEAKER_01: So there's been less of an issue.
- 51:02SPEAKER_01: But I think if you try to give it earlier, both per Rosie or FGR Tigma and Nipo, you know, we're still learning because this is still new and it's continuous.
- 51:10SPEAKER_01: It's gonna be interesting how we're gonna be um changing that off label.
- 51:15SPEAKER_01: Um, but yes, when trying to give it earlier, I have had issues with insurance.
- 51:20SPEAKER_04: Yeah, and I that's my experience as well, is that um even sometimes it varies a little bit by insurance, but even sometimes switching to two weeks on, two weeks off, or every other week dosing is an alternative regimen for FGAR Tigamod or for you know some other more continuous dosing regimen for Rosenolic Sysmab, I've I've sometimes run into issues having it approved.
- 51:40SPEAKER_04: Um, AI is a great tool to write your approval letters.
- 51:44SPEAKER_02: And I I wanted to provide some some clarity on my answer.
- 51:48SPEAKER_02: I haven't had any problems getting the dosing schedule for FGAR Tigamod to four weeks on, three weeks off.
- 51:56SPEAKER_02: Um that particular dosing frequency I have not had any problems with.
- 52:01SPEAKER_04: Thank you.
- 52:02SPEAKER_04: Um as another follow-on question to that, it was sort of talking about, you know, uh continuous versus um cyclical dosing.
- 52:11SPEAKER_04: Um, you know, with nipocalamab being sort of newer and the you know newly available in terms of having continuous dosing, where would you see that fitting in um to your your current practice?
- 52:23SPEAKER_04: Where I imagine, you know, both Rosinolitz and MAD and F-Gartigmod have been on the market for a little while.
- 52:27SPEAKER_04: We probably probably all have several patients on each of those.
- 52:31SPEAKER_04: Where do you see using nipocalamab um, if at all, in in treating your own patients?
- 52:39SPEAKER_02: I would potentially see using it for those treatment refractory patients, patients that may require treatment every two weeks to help um control symptoms rather than the cycles.
- 52:54SPEAKER_01: Yeah.
- 52:54SPEAKER_01: No, I would say that I find the cyclic dosing a little bit frustrating and it can be very um difficult for patients to get better, almost normal, and then to see re-emergence of their symptoms.
- 53:08SPEAKER_01: So I'm I'm excited to offer these different dosing regimens that mimic more continuous dosing, either with NEPO or with our other agents, because I do think that that wearing off is very distressing to our patients.
- 53:22SPEAKER_04: Absolutely.
- 53:24SPEAKER_04: Well, thank you both.
- 53:25SPEAKER_04: I think um, you know, we we are right at the end of our time here.
- 53:29SPEAKER_04: Um, and I just want to take a moment um to uh thank you both for such a robust discussion.
- 53:36SPEAKER_04: Um in terms of uh uh wrapping up, I'd like to review our SMART goals that we uh had sort of set at the beginning of the presentation.
- 53:48SPEAKER_04: Um so summarizing, um, hopefully some of the takeaways can be that you could consider FCRN antagonists for appropriate patients with generalized myasthenia gravis who have a suboptimal response to standard therapy, um, understanding the importance of routinely evaluating quality of life when assessing treatment response so that you can uh see indicators to escalate therapy when needed, um, understand how to discuss treatment options and set realistic treatment goals with patients, and then also understand more about how to monitor response to FCRN antagonists and consider sort of symptom adapted and individualized treatment dosing when appropriate.
- 54:24SPEAKER_04: Um, finally, um, you can visit uh CME Outfitters, visit the neuropsychiatric hub for some resources for healthcare professionals and patients.
- 54:35SPEAKER_04: Thank you so much for joining us this evening.
- 54:37SPEAKER_04: And thank you, Dr.
- 54:38SPEAKER_04: Guayal and Dr.
- 54:38SPEAKER_04: Van Elles, for a lively discussion and fantastic information.
- 54:43SPEAKER_04: Thank you so much.
- 54:45SPEAKER_01: Thank you.